Previous 10 | Next 10 |
- Maintained 34% objective response rate and 79% disease control rate, including two complete responses - XMT-1536 continues to be generally well-tolerated with no new safety signals - Data to be presented and discussed during a conference call today at 8 a.m. ET CAMBRIDG...
In a year dominated by the Covid crisis and the search for a treatment/vaccine, the last week has seen progress in the fight against cancer, and helped send the biotech sector surging. More news on: Gilead Sciences, Inc., Merck & Co., Inc., Immunomedics, Inc., , News on ETFs Read mo...
On Sunday and Monday, September 13th and 14th, two of the largest ever deals for ADC (antibody-drug conjugate) drugs were struck. In a span less than 24 hours, it was announced that Gilead ( GILD ) would pay $21B to purchase Immunomedics (IMMU) for their TROP-2 targeting ADC, Trodelvy, and tha...
Gainers: Immunomedics (NASDAQ: IMMU ) +100% . More news on: Immunomedics, Inc., Cassava Sciences, Inc., Vaxart, Inc., Stocks on the move, , Read more ...
Immunomedics (NASDAQ: IMMU ) +106% after Gilead to buy the company for $21B (~$88/share). More news on: Immunomedics, Inc., Cassava Sciences, Inc., China Natural Resources, Inc., , Stocks on the move, Read more ...
- Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company foc...
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
The biotech industry has been on a tear as the search for coronavirus treatments heat up. Here are four biotech stocks that analysts love: Compugen (CGEN), Cerus (CERS), Mersana Therapeutics (MRSN) and Protagonist Therapeutics (PTGX). Wall Street analysts keep a close eye on price movement,...
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...